首页> 美国卫生研究院文献>BMJ Case Reports >Novel treatment (new drug/intervention; established drug/procedure in new situation): Observations and hypothesis on an individual patient topically treated for capecitabine-induced Palmar-Plantar syndrome
【2h】

Novel treatment (new drug/intervention; established drug/procedure in new situation): Observations and hypothesis on an individual patient topically treated for capecitabine-induced Palmar-Plantar syndrome

机译:新型治疗(新药/干预;新情况下已确立的药物/治疗方法):对局部接受卡培他滨诱导的手足综合征的患者的观察和假设

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Palmar-Plantar syndrome (PPS) is a common side effect of oral capecitabine—a chemotherapeutic agent used as an adjuvant treatment for colorectal cancer. A 66-year-old man suffering from grade II PPS described how Germolene New Skin, a topical healing agent, provided relief from the pain associated with this syndrome and a return to normal function. The patient's observations form the basis for some interesting hypotheses regarding the natural progression of PPS and the potential of New Skin to alleviate pain. Caution must be exercised at this stage as these are single case observations; however, they may be worthy of further exploration in a randomised controlled clinical trial.
机译:Palmar-Plantar综合征(PPS)是口服卡培他滨的常见副作用,卡培他滨是一种化学治疗剂,可作为大肠癌的辅助治疗方法。一位患有II PPS的66岁男性描述了局部康复剂Germolene New Skin如何缓解与该综合征相关的疼痛并恢复正常功能。患者的观察结果构成了一些有趣的假设的基础,这些假设关于PPS的自然进程以及“新皮肤”缓解疼痛的潜力。由于这是单例观察,因此在此阶段必须谨慎。然而,它们可能值得在随机对照临床试验中进一步探索。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号